Filing Flows › BeOne Medicines (ONC) › Gross margin
BeOne Medicines (ONC) gross margin by quarter
BeOne Medicines' gross margin was 88.5% in Q3 2026 (third quarter 2026), -1.2 pts from Q2 2026. Over the last 7 quarters it ranged from 85.2% (Q1 2025) to 90.5% (Q4 2025).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 88.5% | -1.2 pts | +2.4 pts |
| Q2 2026 | 89.8% | +0.8 pts | +2.3 pts |
| Q1 2026 | 89.0% | -1.5 pts | +3.7 pts |
| Q4 2025 | 90.5% | +4.4 pts | — |
| Q3 2025 | 86.1% | -1.4 pts | — |
| Q2 2025 | 87.5% | +2.3 pts | — |
| Q1 2025 | 85.2% | — | — |
Q3 2026 at a glance
BeOne Medicines, Q3 2026: revenue $1.9B (+34% year over year), operating margin 22.2%, net earnings $385M, operating cash flow $509M. The chart follows the revenue to costs, profit and cash.
Questions
What is BeOne Medicines' gross margin?
BeOne Medicines' gross margin was 88.5% in Q3 2026 (third quarter 2026), -1.2 pts from Q2 2026.
How has BeOne Medicines' gross margin changed?
Over the last 7 quarters it ranged from 85.2% (Q1 2025) to 90.5% (Q4 2025).